# ABBV catalysts: AbbVie Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/abbv/catalysts

> AbbVie Inc. (ABBV) has 164 upcoming catalysts. The next is the abbv-rgx-314 dose 1 primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | AbbVie Inc. |
| Ticker | ABBV (NYSE) |
| SEC CIK | 1551152 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/abbv |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 11, 2016 | [Venclexta (venetoclax) FDA approval](https://sec-api.dev/pdufa/venetoclax) | ABBV |  | completed, approved | "NDA208573 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20160411, review_priority PRIORITY; sponsor_name ABBVIE; product VENCLEXTA (VENETOCLAX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208573%22)) |
| June 3, 2016 | [Byvalson (nebivolol hydrochloride; valsartan) FDA approval](https://sec-api.dev/pdufa/nebivolol-valsartan) | ABBV |  | completed, approved | "NDA206302 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20160603, review_priority STANDARD; sponsor_name ABBVIE; product BYVALSON (NEBIVOLOL HYDROCHLORIDE; VALSARTAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA206302%22)) |
| July 22, 2016 | [Viekira Xr (dasabuvir sodium; ombitasvir; paritaprevir; ritonavir) FDA approval](https://sec-api.dev/pdufa/dasabuvir-ombitasvir-paritaprevir-ritonavir) | ABBV |  | completed, approved | "NDA208624 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20160722, review_priority STANDARD; sponsor_name ABBVIE; product VIEKIRA XR (DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208624%22)) |
| June 7, 2017 | [Norvir (ritonavir) FDA approval](https://sec-api.dev/pdufa/ritonavir) | ABBV |  | completed, approved | "NDA209512 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20170607, review_priority PRIORITY; sponsor_name ABBVIE; product NORVIR (RITONAVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209512%22)) |
| August 3, 2017 | [Mavyret (glecaprevir; pibrentasvir) FDA approval](https://sec-api.dev/pdufa/glecaprevir-pibrentasvir) | ABBV |  | completed, approved | "NDA209394 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20170803, review_priority PRIORITY; sponsor_name ABBVIE; product MAVYRET (GLECAPREVIR; PIBRENTASVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209394%22)) |
| February 16, 2018 | [Imbruvica (ibrutinib) FDA approval](https://sec-api.dev/pdufa/ibrutinib) | ABBV |  | completed, approved | "NDA210563 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20180216, review_priority PRIORITY; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210563%22)) |
| July 23, 2018 | [Orilissa (elagolix sodium) FDA approval](https://sec-api.dev/pdufa/elagolix) | ABBV |  | completed, approved | "NDA210450 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180723, review_priority PRIORITY; sponsor_name ABBVIE; product ORILISSA (ELAGOLIX SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210450%22)) |
| April 23, 2019 | [Skyrizi (risankizumab-rzaa) FDA approval](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761105 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190423, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22)) |
| August 16, 2019 | [RINVOQ® (upadacitinib) FDA approval](https://sec-api.dev/pdufa/upadacitinib) | ABBV |  | completed, approved | "NDA211675 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190816, review_priority PRIORITY; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22)) |
| December 23, 2019 | [Ubrelvy (ubrogepant) FDA approval](https://sec-api.dev/pdufa/ubrogepant) | ABBV |  | completed, approved | "NDA211765 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20191223, review_priority STANDARD; sponsor_name ABBVIE; product UBRELVY (UBROGEPANT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211765%22)) |
| January 31, 2020 | [Viibryd (vilazodone hydrochloride) label expansion decision](https://sec-api.dev/pdufa/vilazodone) | ABBV |  | completed, approved | "NDA022567 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20200131, review_priority PRIORITY; sponsor_name ABBVIE; product VIIBRYD (VILAZODONE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022567%22)) |
| March 4, 2020 | [Durysta (bimatoprost) FDA approval](https://sec-api.dev/pdufa/bimatoprost) | ABBV |  | completed, approved | "NDA211911 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20200304, review_priority STANDARD; sponsor_name ABBVIE; product DURYSTA (BIMATOPROST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211911%22)) |
| April 10, 2020 | [Mavyret (glecaprevir; pibrentasvir) label expansion decision](https://sec-api.dev/pdufa/glecaprevir-pibrentasvir) | ABBV |  | completed, approved | "NDA209394 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20200410, review_priority STANDARD; sponsor_name ABBVIE; product MAVYRET (GLECAPREVIR; PIBRENTASVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209394%22)) |
| April 21, 2020 | [Imbruvica (ibrutinib) label expansion decision](https://sec-api.dev/pdufa/ibrutinib) | ABBV |  | completed, approved | "NDA210563 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20200421, review_priority PRIORITY; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210563%22)) |
| May 29, 2020 | [Oriahnn (Copackaged) (elagolix sodium; elagolix sodium,estradiol,norethindrone acetate) FDA approval](https://sec-api.dev/pdufa/elagolix-elagolix-estradiol-norethindrone) | ABBV |  | completed, approved | "NDA213388 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20200529, review_priority STANDARD; sponsor_name ABBVIE; product ORIAHNN (COPACKAGED) (ELAGOLIX SODIUM; ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213388%22)) |
| July 8, 2020 | [Botox Cosmetic (onabotulinumtoxina) label expansion decision](https://sec-api.dev/pdufa/onabotulinumtoxina) | ABBV |  | completed, approved | "BLA103000 SUPPL-5315 (Efficacy): submission_status AP, submission_status_date 20200708, review_priority STANDARD; sponsor_name ALLERGAN; product BOTOX COSMETIC (OnabotulinumtoxinA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA103000%22)) |
| September 22, 2020 | [LINZESS® (linaclotide) label expansion decision](https://sec-api.dev/pdufa/linaclotide) | ABBV |  | completed, approved | "NDA202811 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20200922, review_priority STANDARD; sponsor_name ABBVIE; product LINZESS (LINACLOTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202811%22)) |
| October 16, 2020 | [Venclexta (venetoclax) label expansion decision](https://sec-api.dev/pdufa/venetoclax) | ABBV |  | completed, approved | "NDA208573 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20201016, review_priority PRIORITY; sponsor_name ABBVIE; product VENCLEXTA (VENETOCLAX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208573%22)) |
| December 16, 2020 | [AMJEVITA® (adalimumab) label expansion decision](https://sec-api.dev/pdufa/adalimumab) | ABBV |  | completed, approved | "BLA125057 SUPPL-419 (Efficacy): submission_status AP, submission_status_date 20201216, review_priority STANDARD; sponsor_name ABBVIE INC; product HUMIRA (ADALIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125057%22)) |
| December 18, 2020 | [Imbruvica (ibrutinib) label expansion decision](https://sec-api.dev/pdufa/ibrutinib) | ABBV |  | completed, approved | "NDA210563 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20201218, review_priority STANDARD; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210563%22)) |
| February 1, 2021 | [Orilissa (elagolix sodium) label expansion decision](https://sec-api.dev/pdufa/elagolix) | ABBV |  | completed, approved | "NDA210450 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20210201, review_priority STANDARD; sponsor_name ABBVIE; product ORILISSA (ELAGOLIX SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210450%22)) |
| February 9, 2021 | [Botox Cosmetic (onabotulinumtoxina) label expansion decision](https://sec-api.dev/pdufa/onabotulinumtoxina) | ABBV |  | completed, approved | "BLA103000 SUPPL-5318 (Efficacy): submission_status AP, submission_status_date 20210209, review_priority STANDARD; sponsor_name ALLERGAN; product BOTOX COSMETIC (OnabotulinumtoxinA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA103000%22)) |
| February 24, 2021 | [AMJEVITA® (adalimumab) label expansion decision](https://sec-api.dev/pdufa/adalimumab) | ABBV |  | completed, approved | "BLA125057 SUPPL-417 (Efficacy): submission_status AP, submission_status_date 20210224, review_priority STANDARD; sponsor_name ABBVIE INC; product HUMIRA (ADALIMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125057%22)) |
| April 26, 2021 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761105 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20210426, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22)) |
| June 10, 2021 | [Mavyret (glecaprevir; pibrentasvir) FDA approval](https://sec-api.dev/pdufa/glecaprevir-pibrentasvir) | ABBV |  | completed, approved | "NDA215110 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20210610, review_priority PRIORITY; sponsor_name ABBVIE; product MAVYRET (GLECAPREVIR; PIBRENTASVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215110%22)) |
| June 10, 2021 | [Mavyret (glecaprevir; pibrentasvir) label expansion decision](https://sec-api.dev/pdufa/glecaprevir-pibrentasvir) | ABBV |  | completed, approved | "NDA209394 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20210610, review_priority PRIORITY; sponsor_name ABBVIE; product MAVYRET (GLECAPREVIR; PIBRENTASVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209394%22)) |
| July 22, 2021 | [Dalvance (dalbavancin hydrochloride) label expansion decision](https://sec-api.dev/pdufa/dalbavancin) | ABBV |  | completed, approved | "NDA021883 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20210722, review_priority STANDARD; sponsor_name ABBVIE; product DALVANCE (DALBAVANCIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021883%22)) |
| July 28, 2021 | [Botox Cosmetic (onabotulinumtoxina) label expansion decision](https://sec-api.dev/pdufa/onabotulinumtoxina) | ABBV |  | completed, approved | "BLA103000 SUPPL-5320 (Efficacy): submission_status AP, submission_status_date 20210728, review_priority STANDARD; sponsor_name ALLERGAN; product BOTOX COSMETIC (OnabotulinumtoxinA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA103000%22)) |
| September 28, 2021 | [Qulipta (atogepant) FDA approval](https://sec-api.dev/pdufa/atogepant) | ABBV |  | completed, approved | "NDA215206 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210928, review_priority PRIORITY; sponsor_name ABBVIE; product QULIPTA (ATOGEPANT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215206%22)) |
| October 4, 2021 | [Venclexta (venetoclax) label expansion decision](https://sec-api.dev/pdufa/venetoclax) | ABBV |  | completed, approved | "NDA208573 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20211004, review_priority STANDARD; sponsor_name ABBVIE; product VENCLEXTA (VENETOCLAX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208573%22)) |
| October 28, 2021 | [Vuity (pilocarpine hydrochloride) FDA approval](https://sec-api.dev/pdufa/pilocarpine) | ABBV |  | completed, approved | "NDA214028 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20211028, review_priority STANDARD; sponsor_name ABBVIE; product VUITY (PILOCARPINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214028%22)) |
| December 10, 2021 | [Lastacaft (alcaftadine) label expansion decision](https://sec-api.dev/pdufa/alcaftadine) | ABBV |  | completed, approved | "NDA022134 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20211210, review_priority STANDARD; sponsor_name ABBVIE; product LASTACAFT (ALCAFTADINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022134%22)) |
| December 14, 2021 | [RINVOQ® (upadacitinib) label expansion decision](https://sec-api.dev/pdufa/upadacitinib) | ABBV |  | completed, approved | "NDA211675 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20211214, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22)) |
| January 14, 2022 | [RINVOQ® (upadacitinib) label expansion decision](https://sec-api.dev/pdufa/upadacitinib) | ABBV |  | completed, approved | "NDA211675 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20220114, review_priority PRIORITY; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22)) |
| January 21, 2022 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761105 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20220121, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22)) |
| March 16, 2022 | [RINVOQ® (upadacitinib) label expansion decision](https://sec-api.dev/pdufa/upadacitinib) | ABBV |  | completed, approved | "NDA211675 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20220316, review_priority PRIORITY; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22)) |
| April 18, 2022 | [Lupron Depot (leuprolide acetate) label expansion decision](https://sec-api.dev/pdufa/leuprolide) | ABBV |  | completed, approved | "NDA020517 SUPPL-43 (Efficacy): submission_status AP, submission_status_date 20220418, review_priority STANDARD; sponsor_name ABBVIE ENDOCRINE INC; product LUPRON DEPOT (LEUPROLIDE ACETATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA020517%22)) |
| April 29, 2022 | [RINVOQ® (upadacitinib) label expansion decision](https://sec-api.dev/pdufa/upadacitinib) | ABBV |  | completed, approved | "NDA211675 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20220429, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22)) |
| June 16, 2022 | [Skyrizi (risankizumab-rzaa) FDA approval](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761262 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20220616, review_priority PRIORITY; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761262%22)) |
| June 16, 2022 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761105 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20220616, review_priority PRIORITY; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22)) |
| August 24, 2022 | [Imbruvica (ibrutinib) FDA approval](https://sec-api.dev/pdufa/ibrutinib) | ABBV |  | completed, approved | "NDA217003 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20220824, review_priority PRIORITY; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217003%22)) |
| August 24, 2022 | [Imbruvica (ibrutinib) label expansion decision](https://sec-api.dev/pdufa/ibrutinib) | ABBV |  | completed, approved | "NDA210563 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20220824, review_priority PRIORITY; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210563%22)) |
| September 23, 2022 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761105 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20220923, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22)) |
| October 21, 2022 | [RINVOQ® (upadacitinib) label expansion decision](https://sec-api.dev/pdufa/upadacitinib) | ABBV |  | completed, approved | "NDA211675 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20221021, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22)) |
| December 16, 2022 | [Vraylar (cariprazine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/cariprazine) | ABBV |  | completed, approved | "NDA204370 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20221216, review_priority STANDARD; sponsor_name ABBVIE; product VRAYLAR (CARIPRAZINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204370%22)) |
| December 20, 2022 | [Avycaz (avibactam sodium; ceftazidime) label expansion decision](https://sec-api.dev/pdufa/avibactam-ceftazidime) | ABBV |  | completed, approved | "NDA206494 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20221220, review_priority PRIORITY; sponsor_name ABBVIE; product AVYCAZ (AVIBACTAM SODIUM; CEFTAZIDIME)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA206494%22)) |
| March 17, 2023 | [Vyalev (foscarbidopa; foslevodopa) complete response letter (CRL)](https://sec-api.dev/pdufa/foscarbidopa-foslevodopa) | ABBV |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22216962_2025_Orig1s000OtherActionLtrs.pdf%22)) |
| March 24, 2023 | [Fetzima (levomilnacipran hydrochloride) label expansion decision](https://sec-api.dev/pdufa/levomilnacipran) | ABBV |  | completed, approved | "NDA204168 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20230324, review_priority STANDARD; sponsor_name ABBVIE; product FETZIMA (LEVOMILNACIPRAN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204168%22)) |
| March 28, 2023 | [Vuity (pilocarpine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/pilocarpine) | ABBV |  | completed, approved | "NDA214028 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20230328, review_priority STANDARD; sponsor_name ABBVIE; product VUITY (PILOCARPINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214028%22)) |
| April 14, 2023 | [Lupron Depot (leuprolide acetate) label expansion decision](https://sec-api.dev/pdufa/leuprolide) | ABBV |  | completed, approved | "NDA020263 SUPPL-53 (Efficacy): submission_status AP, submission_status_date 20230414, review_priority STANDARD; sponsor_name ABBVIE ENDOCRINE INC; product LUPRON DEPOT-PED KIT (LEUPROLIDE ACETATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA020263%22)) |
| April 17, 2023 | [Qulipta (atogepant) label expansion decision](https://sec-api.dev/pdufa/atogepant) | ABBV |  | completed, approved | "NDA215206 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20230417, review_priority STANDARD; sponsor_name ABBVIE; product QULIPTA (ATOGEPANT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215206%22)) |
| May 12, 2023 | [Lexapro (escitalopram oxalate) label expansion decision](https://sec-api.dev/pdufa/escitalopram-oxalate) | ABBV |  | completed, approved | "NDA021365 SUPPL-39 (Efficacy): submission_status AP, submission_status_date 20230512, review_priority STANDARD; sponsor_name ABBVIE; product LEXAPRO (ESCITALOPRAM OXALATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021365%22)) |
| May 18, 2023 | [Imbruvica (ibrutinib) label expansion decision](https://sec-api.dev/pdufa/ibrutinib) | ABBV |  | completed, approved | "NDA210563 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20230518, review_priority STANDARD; sponsor_name PHARMACYCLICS LLC; product IMBRUVICA (IBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210563%22)) |
| May 18, 2023 | [RINVOQ® (upadacitinib) label expansion decision](https://sec-api.dev/pdufa/upadacitinib) | ABBV |  | completed, approved | "NDA211675 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20230518, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22)) |
| June 12, 2023 | [LINZESS® (linaclotide) label expansion decision](https://sec-api.dev/pdufa/linaclotide) | ABBV |  | completed, approved | "NDA202811 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20230612, review_priority PRIORITY; sponsor_name ABBVIE; product LINZESS (LINACLOTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202811%22)) |
| June 22, 2023 | [RINVOQ® (upadacitinib) label expansion decision](https://sec-api.dev/pdufa/upadacitinib) | ABBV |  | completed, approved | "NDA211675 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20230622, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22)) |
| August 11, 2023 | [Botox Cosmetic (onabotulinumtoxina) label expansion decision](https://sec-api.dev/pdufa/onabotulinumtoxina) | ABBV |  | completed, approved | "BLA103000 SUPPL-5325 (Efficacy): submission_status AP, submission_status_date 20230811, review_priority STANDARD; sponsor_name ALLERGAN; product BOTOX COSMETIC (OnabotulinumtoxinA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA103000%22)) |
| January 26, 2024 | [Avycaz (avibactam sodium; ceftazidime) label expansion decision](https://sec-api.dev/pdufa/avibactam-ceftazidime) | ABBV |  | completed, approved | "NDA206494 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20240126, review_priority PRIORITY; sponsor_name ABBVIE; product AVYCAZ (AVIBACTAM SODIUM; CEFTAZIDIME)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA206494%22)) |
| Apr 2024 | [Dupixent (dupilumab) topline data readout](https://sec-api.dev/pdufa/dupilumab) | ABBV |  | completed, positive | "•In April 2024, AbbVie announced positive top-line results from the head-to-head Phase 3b/4 Level-Up trial evaluating Rinvoq compared to dupilumab in adolescent and adult patients with moderate to severe atopic dermatitis." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm)) |
| April 26, 2024 | [RINVOQ® (upadacitinib) FDA approval](https://sec-api.dev/pdufa/upadacitinib) | ABBV |  | completed, approved | "NDA218347 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240426, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ LQ (UPADACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218347%22)) |
| April 26, 2024 | [RINVOQ® (upadacitinib) label expansion decision](https://sec-api.dev/pdufa/upadacitinib) | ABBV |  | completed, approved | "NDA211675 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20240426, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22)) |
| Jun 2024 | [AbbVie Inc. topline data readout](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed, positive | "•In June 2024, AbbVie announced positive topline results from the Phase 2 PICCOLO trial evaluating Elahere monotherapy in heavily pre-treated patients with FRα-positive, platinum-sensitive ovarian cancer." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm)) |
| June 18, 2024 | [Vyalev (foscarbidopa; foslevodopa) complete response letter (CRL)](https://sec-api.dev/pdufa/foscarbidopa-foslevodopa) | ABBV |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22216962_2025_Orig1s000OtherActionLtrs.pdf%22)) |
| June 18, 2024 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761262 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20240618, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761262%22)) |
| Sep 2024 | [Juvmo (tavapadon) topline data readout](https://sec-api.dev/pdufa/tavapadon) | ABBV |  | completed, positive | "•In September 2024, AbbVie announced positive top-line results from its Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm)) |
| October 16, 2024 | [Vyalev (foscarbidopa; foslevodopa) FDA approval](https://sec-api.dev/pdufa/foscarbidopa-foslevodopa) | ABBV |  | completed, approved | "NDA216962 ORIG-1 (Type 3 - New Dosage Form and Type 4 - New Combination): submission_status AP, submission_status_date 20241016, review_priority STANDARD; sponsor_name ABBVIE; product VYALEV (FOSCARBIDOPA; FOSLEVODOPA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216962%22)) |
| October 18, 2024 | [Botox Cosmetic (onabotulinumtoxina) label expansion decision](https://sec-api.dev/pdufa/onabotulinumtoxina) | ABBV |  | completed, approved | "BLA103000 SUPPL-5331 (Efficacy): submission_status AP, submission_status_date 20241018, review_priority STANDARD; sponsor_name ALLERGAN; product BOTOX COSMETIC (OnabotulinumtoxinA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA103000%22)) |
| Dec 2024 | [Juvmo (tavapadon) topline data readout](https://sec-api.dev/pdufa/tavapadon) | ABBV |  | completed, positive | "•In December 2024, AbbVie announced positive top-line results from its pivotal Phase 3 TEMPO-2 trial evaluating tavapadon as a flexible-dose monotherapy in early Parkinson's disease." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000020/abbv-20241231.htm)) |
| January 31, 2025 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000011/abbv-20241231xexhibit991.htm)) |
| February 7, 2025 | [Emblaveo (avibactam sodium; aztreonam) FDA approval](https://sec-api.dev/pdufa/avibactam-aztreonam) | ABBV |  | completed, approved | "NDA217906 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20250207, review_priority PRIORITY; sponsor_name ABBVIE; product EMBLAVEO (AVIBACTAM SODIUM; AZTREONAM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217906%22)) |
| April 25, 2025 | [Avibactam FDA approval](https://sec-api.dev/pdufa/avibactam) | ABBV | complicated intra-abdominal infections | completed, approved | "•AbbVie announced that the FDA approved Emblaveo (aztreonam and avibactam), as the first monobactam/β-lactamase inhibitor combination antibiotic therapy to treat complicated intra-abdominal infections, including those caused by Gram-negative bacteria." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000026/abbv-20250331xexhibit991.htm)) |
| April 25, 2025 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports First-Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000026/abbv-20250331xexhibit991.htm)) |
| April 25, 2025 | [GUB014295 NDA/BLA submission](https://sec-api.dev/pdufa/gub014295) | ABBV | moderate to severe glabellar lines | completed | "•AbbVie announced that it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of trenibotulinumtoxinE (BoNT/E) for the treatment of moderate to severe glabellar lines." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000026/abbv-20250331xexhibit991.htm)) |
| April 28, 2025 | [RINVOQ® (upadacitinib) label expansion decision](https://sec-api.dev/pdufa/upadacitinib) | ABBV |  | completed, approved | "NDA211675 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20250428, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22)) |
| May 2, 2025 | [Qulipta (atogepant) primary completion](https://sec-api.dev/pdufa/atogepant) | ABBV | Chronic Migraine | completed | "NCT05216263 (Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-02 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-06-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05216263)) |
| May 8, 2025 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Mid Face Volume Deficit | completed | "NCT05452070 (A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Allergan." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05452070)) |
| May 14, 2025 | [Emrelis (telisotuzumab vedotin-tllv) FDA approval](https://sec-api.dev/pdufa/telisotuzumab-vedotin-tllv) | ABBV |  | completed, approved | "Emrelis \| telisotuzumab vedotin-tllv \| 5/14/2025 \| To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| May 22, 2025 | [Lupron Depot (leuprolide acetate) label expansion decision](https://sec-api.dev/pdufa/leuprolide) | ABBV |  | completed, approved | "NDA020263 SUPPL-56 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority STANDARD; sponsor_name ABBVIE ENDOCRINE INC; product LUPRON DEPOT-PED KIT (LEUPROLIDE ACETATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA020263%22)) |
| May 30, 2025 | [Nx-13 250mg primary completion](https://sec-api.dev/pdufa/nx-13) | ABBV | Ulcerative Colitis | withdrawn | "NCT05785715 (Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-06-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05785715)) |
| June 5, 2025 | [Irritable bowel syndrome with constipation (ibs-c) participants (lin-md-63 and lin-md-64 completers) primary completion](https://sec-api.dev/pdufa/irritable-bowel-syndrome-with-constipation-ibs-c-participants-lin-md-63-and-lin-) | ABBV | Irritable Bowel Syndrome With Constipation; Functional Constipation | completed | "NCT04166058 (Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-01-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04166058)) |
| June 9, 2025 | [Paricalcitol primary completion](https://sec-api.dev/pdufa/paricalcitol) | ABBV | Chronic Kidney Disease (CKD); Secondary Hyperparathyroidism (SHPT) | withdrawn | "NCT04064827 (A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-06-09 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-06-15." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04064827)) |
| June 9, 2025 | [LINZESS® (linaclotide) primary completion](https://sec-api.dev/pdufa/linaclotide) | ABBV | Functional Constipation | completed | "NCT05760313 (A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-09 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-01-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05760313)) |
| June 10, 2025 | [Mavyret (glecaprevir; pibrentasvir) label expansion decision](https://sec-api.dev/pdufa/glecaprevir-pibrentasvir) | ABBV |  | completed, approved | "NDA209394 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20250610, review_priority PRIORITY; sponsor_name ABBVIE; product MAVYRET (GLECAPREVIR; PIBRENTASVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209394%22)) |
| June 25, 2025 | [Emraclidine primary completion](https://sec-api.dev/pdufa/emraclidine) | ABBV | Schizophrenia | withdrawn | "NCT05443724 (A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-06-25 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-08-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05443724)) |
| Jul 2025 | [AbbVie Inc. topline data readout](https://sec-api.dev/companies/abbv/catalysts) | ABBV | history of four or more migraine days per month | completed, positive | "•In July 2025, AbbVie announced positive topline results from Study 2 of its Phase 3 UP-AA trial for Rinvoq as a monotherapy in adults and adolescents with severe alopecia areata (AA)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm)) |
| July 7, 2025 | [Qulipta (atogepant) primary completion](https://sec-api.dev/pdufa/atogepant) | ABBV | Migraine | completed | "NCT06241313 (Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-07 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06241313)) |
| July 18, 2025 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Crohn's Disease (CD) | completed | "NCT02782663 (A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-18 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02782663)) |
| July 31, 2025 | [Telisotuzumab vedotin FDA approval](https://sec-api.dev/pdufa/telisotuzumab-vedotin) | ABBV |  | completed, approved | "•AbbVie announced that Emrelis (telisotuzumab vedotin-tllv) was granted accelerated approval by the FDA for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression who have received a prior systemic therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/abbv-20250630xexhibit991.htm)) |
| July 31, 2025 | [Glecaprevir label expansion decision](https://sec-api.dev/pdufa/glecaprevir) | ABBV |  | completed, approved | "•AbbVie announced the FDA approved a label expansion for Mavyret (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA) therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/abbv-20250630xexhibit991.htm)) |
| July 31, 2025 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports Second-Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/abbv-20250630xexhibit991.htm)) |
| July 31, 2025 | [RINVOQ® (upadacitinib) FDA approval](https://sec-api.dev/pdufa/upadacitinib) | ABBV | with giant cell arteritis | completed, approved | "•AbbVie announced the U.S. Food and Drug Administration (FDA) approved Rinvoq (upadacitinib) as the first oral Janus Kinase (JAK) inhibitor approved for the treatment of adults with giant cell arteritis (GCA)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/abbv-20250630xexhibit991.htm)) |
| July 31, 2025 | [Botox primary completion](https://sec-api.dev/pdufa/botox) | ABBV | Masseter Muscle Prominence | completed | "NCT06137287 (A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-31 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06137287)) |
| August 8, 2025 | [Bimatoprost sr primary completion](https://sec-api.dev/pdufa/bimatoprost-sr) | ABBV | Open-Angle Glaucoma; Ocular Hypertension | completed | "NCT03850782 (Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-08 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-11-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03850782)) |
| September 2, 2025 | [LINZESS® (linaclotide) primary completion](https://sec-api.dev/pdufa/linaclotide) | ABBV | Functional Constipation (FC); Chronic Idiopathic Constipation (CIC) | completed | "NCT05652205 (A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-05-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05652205)) |
| September 3, 2025 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761262 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20250903, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761262%22)) |
| September 22, 2025 | [ABBV-382 primary completion](https://sec-api.dev/pdufa/abbv-382) | ABBV | Human Immuno-deficiency Virus (HIV) Disease | withdrawn | "NCT06032546 (A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-09-22 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-11-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06032546)) |
| September 23, 2025 | [Venclexta (venetoclax) primary completion](https://sec-api.dev/pdufa/venetoclax) | ABBV | Acute Myeloid Leukemia (AML); Cancer | withdrawn | "NCT04161885 (A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-09-23 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-06-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04161885)) |
| Oct 2025 | [AbbVie Inc. topline data readout](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed, positive | "•In October 2025, AbbVie announced positive topline results from two replicate Phase 3 studies evaluating the efficacy and safety of Rinvoq in adult and adolescent patients with non-segmental vitiligo." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm)) |
| Oct 2025 | [AbbVie Inc. topline data readout](https://sec-api.dev/companies/abbv/catalysts) | ABBV | moderate to severe rheumatoid arthritis | completed, positive | "•In October 2025, AbbVie announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of Rinvoq compared to Humira in adult patients with moderate to severe rheumatoid arthritis (RA), who had an inadequate response or intolerance to a single TNF inhibitor other than Humira." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm)) |
| October 6, 2025 | [Cariprazine flexible dose primary completion](https://sec-api.dev/pdufa/cariprazine-flexible-dose) | ABBV | Schizophrenia; Bipolar I Disorder; Autism Spectrum Disorder (ASD) | completed | "NCT04578756 (Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-06 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04578756)) |
| October 9, 2025 | [Venclexta (venetoclax) primary completion](https://sec-api.dev/pdufa/venetoclax) | ABBV | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) | completed | "NCT05105841 (Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-09 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05105841)) |
| October 10, 2025 | [RINVOQ® (upadacitinib) label expansion decision](https://sec-api.dev/pdufa/upadacitinib) | ABBV |  | completed, approved | "NDA211675 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20251010, review_priority STANDARD; sponsor_name ABBVIE; product RINVOQ (UPADACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211675%22)) |
| October 20, 2025 | [Qulipta (atogepant) primary completion](https://sec-api.dev/pdufa/atogepant) | ABBV | Episodic Migraine; Chronic Migraine | completed | "NCT04686136 (A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-20 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04686136)) |
| October 31, 2025 | [Juvmo (tavapadon) NDA/BLA submission](https://sec-api.dev/pdufa/tavapadon) | ABBV | Parkinson's disease | completed | "•AbbVie announced that it submitted a New Drug Application (NDA) to the FDA for tavapadon, a novel selective dopamine D1/D5 receptor partial agonist for the treatment of Parkinson's disease (PD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/abbv-20250930xexhibit991.htm)) |
| October 31, 2025 | [RINVOQ® (upadacitinib) label expansion decision](https://sec-api.dev/pdufa/upadacitinib) | ABBV | with moderately to severely active ulcerative colitis | completed, approved | "•AbbVie announced the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) that updates the indication statement for Rinvoq (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/abbv-20250930xexhibit991.htm)) |
| October 31, 2025 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports Third-Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/abbv-20250930xexhibit991.htm)) |
| November 4, 2025 | [LINZESS® (linaclotide) label expansion decision](https://sec-api.dev/pdufa/linaclotide) | ABBV |  | completed, approved | "NDA202811 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20251104, review_priority PRIORITY; sponsor_name ABBVIE; product LINZESS (LINACLOTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202811%22)) |
| November 10, 2025 | [Botox primary completion](https://sec-api.dev/pdufa/botox) | ABBV | Masseter Muscle Prominence | completed | "NCT06399718 (A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-10 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06399718)) |
| November 12, 2025 | [ABBV-932 primary completion](https://sec-api.dev/pdufa/abbv-932) | ABBV | Bipolar I Disorder; Bipolar II Disorder | completed | "NCT06605599 (Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-12 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06605599)) |
| November 19, 2025 | [ABBV-916 primary completion](https://sec-api.dev/pdufa/abbv-916) | ABBV | Alzheimer's Disease (AD) | completed | "NCT05291234 (A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-19 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05291234)) |
| November 20, 2025 | [Botox primary completion](https://sec-api.dev/pdufa/botox) | ABBV | Masseter Muscle Prominence | completed | "NCT06068855 (A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-20 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06068855)) |
| November 25, 2025 | [Botox primary completion](https://sec-api.dev/pdufa/botox) | ABBV | Masseter Muscle Prominence | completed | "NCT06387394 (A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-25 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06387394)) |
| December 1, 2025 | [Juvmo (tavapadon) primary completion](https://sec-api.dev/pdufa/tavapadon) | ABBV | Parkinson Disease | completed | "NCT04760769 (Open-label Trial in Parkinson's Disease (PD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-01 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04760769)) |
| December 5, 2025 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Facial Volume Deficit | completed | "NCT05818709 (A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-05 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05818709)) |
| December 18, 2025 | [Vraylar (cariprazine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/cariprazine) | ABBV |  | completed, approved | "NDA204370 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20251218, review_priority PRIORITY; sponsor_name ABBVIE; product VRAYLAR (CARIPRAZINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204370%22)) |
| January 6, 2026 | [Irritable bowel syndrome with constipation (ibs-c) participants (lin-md-63 and lin-md-64 completers) topline data readout](https://sec-api.dev/pdufa/irritable-bowel-syndrome-with-constipation-ibs-c-participants-lin-md-63-and-lin-) | ABBV | Irritable Bowel Syndrome With Constipation; Functional Constipation | completed | "NCT04166058 (Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-05 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-01-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04166058?tab=results)) |
| January 6, 2026 | [LINZESS® (linaclotide) topline data readout](https://sec-api.dev/pdufa/linaclotide) | ABBV | Functional Constipation | completed | "NCT05760313 (A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-09 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-01-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05760313?tab=results)) |
| January 26, 2026 | [Elezanumab primary completion](https://sec-api.dev/pdufa/elezanumab) | ABBV | Spinal Cord Injury (SCI) | completed | "NCT04295538 (Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-26 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04295538)) |
| Feb 2026 | [AbbVie Inc. topline data readout](https://sec-api.dev/companies/abbv/catalysts) | ABBV | moderately to severely active Crohn's disease | completed, positive | "•In February 2026, AbbVie announced positive topline results from the Phase 3 AFFIRM trial evaluating Skyrizi subcutaneous induction in adult patients with moderately to severely active Crohn's disease (CD)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/abbv-20260930.htm)) |
| February 4, 2026 | [TEPKINLY (epcoritamab) FDA approval](https://sec-api.dev/pdufa/epcoritamab) | ABBV |  | completed, approved | "•AbbVie announced the FDA approval of Epkinly (epcoritamab) in combination with rituximab and lenalidomide (R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000004/abbv-20251231xexhibit991.htm)) |
| February 4, 2026 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000004/abbv-20251231xexhibit991.htm)) |
| February 4, 2026 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Open-Angle Glaucoma | completed | "NCT05411198 (Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-04 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05411198)) |
| February 5, 2026 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Skin Quality Deficit | completed | "NCT06547125 (A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Quality): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2026-02-05 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06547125)) |
| February 19, 2026 | [Venclexta (venetoclax) label expansion decision](https://sec-api.dev/pdufa/venetoclax) | ABBV |  | completed, approved | "NDA208573 SUPPL-31 (Efficacy): submission_status AP, submission_status_date 20260219, review_priority STANDARD; sponsor_name ABBVIE; product VENCLEXTA (VENETOCLAX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208573%22)) |
| March 6, 2026 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761105 SUPPL-42 (Efficacy): submission_status AP, submission_status_date 20260306, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22)) |
| April 3, 2026 | [Botox Cosmetic (onabotulinumtoxina) primary completion](https://sec-api.dev/pdufa/onabotulinumtoxina) | ABBV | Forehead Lines | completed | "NCT06794866 (A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-03 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06794866)) |
| April 17, 2026 | [Foscarbidopa primary completion](https://sec-api.dev/pdufa/foscarbidopa) | ABBV | Parkinson's Disease (PD) | completed | "NCT04379050 (Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-17 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04379050)) |
| April 22, 2026 | [AGN-151586 complete response letter (CRL)](https://sec-api.dev/pdufa/agn-151586) | ABBV |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761459_20260422.pdf%22)) |
| April 27, 2026 | [Foscarbidopa primary completion](https://sec-api.dev/pdufa/foscarbidopa) | ABBV | Parkinson's Disease (PD) | completed | "NCT04750226 (Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-27 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04750226)) |
| April 29, 2026 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports First-Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000013/abbv-20260331xexhibit991.htm)) |
| April 29, 2026 | [AbbVie Inc. complete response letter (CRL)](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed, complete response letter | "•AbbVie announced it received a Complete Response Letter (CRL) from the FDA regarding the Biologics License Application (BLA) for trenibotulinumtoxinE (trenibotE), a first-in-class botulinum neurotoxin serotype E with a rapid onset of effect and short duration." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000013/abbv-20260331xexhibit991.htm)) |
| May 14, 2026 | [LINZESS® (linaclotide) topline data readout](https://sec-api.dev/pdufa/linaclotide) | ABBV | Functional Constipation (FC); Chronic Idiopathic Constipation (CIC) | completed | "NCT05652205 (A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-02 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-05-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05652205?tab=results)) |
| May 20, 2026 | [Venclexta (venetoclax) label expansion decision](https://sec-api.dev/pdufa/venetoclax) | ABBV |  | completed, approved | "NDA208573 SUPPL-32 (Efficacy): submission_status AP, submission_status_date 20260520, review_priority STANDARD; sponsor_name ABBVIE; product VENCLEXTA (VENETOCLAX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208573%22)) |
| May 21, 2026 | [LINZESS® (linaclotide) label expansion decision](https://sec-api.dev/pdufa/linaclotide) | ABBV |  | completed, approved | "NDA202811 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20260521, review_priority PRIORITY; sponsor_name ABBVIE; product LINZESS (LINACLOTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202811%22)) |
| May 27, 2026 | [Decnupaz (pivekimab sunirine-pvzy) FDA approval](https://sec-api.dev/pdufa/pivekimab-sunirine-pvzy) | ABBV | To treat adults with blastic plasmacytoid dendritic cell neoplasm | completed, approved | "Decnupaz \| pivekimab sunirine-pvzy \| 5/27/2026 \| To treat adults with blastic plasmacytoid dendritic cell neoplasmDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| June 12, 2026 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761105 SUPPL-44 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22)) |
| June 16, 2026 | [Qulipta (atogepant) topline data readout](https://sec-api.dev/pdufa/atogepant) | ABBV | Chronic Migraine | completed | "NCT05216263 (Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-02 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-06-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05216263?tab=results)) |
| June 18, 2026 | [Abbv-rgx-314 dose 1 primary completion](https://sec-api.dev/pdufa/abbv-rgx-314) | ABBV | Diabetic Retinopathy (DR); Center-Involved Diabetic Macular Edema (CI-DME) | completed | "NCT04567550 (RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-18 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04567550)) |
| June 19, 2026 | [Bimatoprost sr primary completion](https://sec-api.dev/pdufa/bimatoprost-sr) | ABBV | Open-Angle Glaucoma; Ocular Hypertension | completed | "NCT03891446 (Long-term Safety and Efficacy Extension Trial of Bimatoprost SR): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-19 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03891446)) |
| June 26, 2026 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761105 SUPPL-45 (Efficacy): submission_status AP, submission_status_date 20260626, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22)) |
| June 29, 2026 | [Qulipta (atogepant) primary completion](https://sec-api.dev/pdufa/atogepant) | ABBV | Menstrual Migraine (MM) | completed | "NCT06806293 (Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-29 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06806293)) |
| July 2026 | [Telisotuzumab vedotin primary completion](https://sec-api.dev/pdufa/telisotuzumab-vedotin) | ABBV | Non-small Cell Lung Cancer | delayed | "NCT03539536 (Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03539536)) |
| July 2026 | [Mirvetuximab soravtansine primary completion](https://sec-api.dev/pdufa/mirvetuximab-soravtansine) | ABBV |  | delayed | "NCT06682988 (A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06682988)) |
| July 14, 2026 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Atrophic Acne Scars | completed | "NCT05995340 (ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-14 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05995340)) |
| July 15, 2026 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Rheumatoid Arthritis | completed | "NCT05814627 (Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-15 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05814627)) |
| July 27, 2026 | [GM-2505 primary completion](https://sec-api.dev/pdufa/gm-2505) | ABBV | Major Depressive Disorder | completed | "NCT06236880 (A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-27 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06236880)) |
| July 31, 2026 | [GAZYVA® (obinutuzumab) FDA approval](https://sec-api.dev/pdufa/obinutuzumab) | ABBV |  | completed, approved | "•Allergan Aesthetics announced the FDA approved Skinvive by Juvederm as the first hyaluronic acid injectable indicated to reduce neck lines for the improvement of neck appearance in adults over the age of 21." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm)) |
| July 31, 2026 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports Second-Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm)) |
| July 31, 2026 | [Pivekimab FDA approval](https://sec-api.dev/pdufa/pivekimab) | ABBV |  | completed, approved | "•AbbVie announced the FDA approved Decnupaz (pivekimab sunirine) for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive hematologic malignancy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000023/abbv-20260630xexhibit991.htm)) |
| August 2026 | [Venclexta (venetoclax) primary completion](https://sec-api.dev/pdufa/venetoclax) | ABBV | Multiple Myeloma | delayed | "NCT03539744 (A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03539744)) |
| Aug to Nov 2026 | [Venclexta (venetoclax) topline data readout](https://sec-api.dev/pdufa/venetoclax) | ABBV | Multiple Myeloma | scheduled | "NCT03539744 (A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03539744)) |
| August 2026 | [Lucentis® (ranibizumab) primary completion](https://sec-api.dev/pdufa/ranibizumab) | ABBV | Neovascular Age-Related Macular Degeneration (nAMD) | delayed | "NCT04514653 (RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04514653)) |
| Aug to Nov 2026 | [Lucentis® (ranibizumab) topline data readout](https://sec-api.dev/pdufa/ranibizumab) | ABBV | Neovascular Age-Related Macular Degeneration (nAMD) | scheduled | "NCT04514653 (RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04514653)) |
| August 13, 2026 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Crohn's Disease (CD) | completed | "NCT02782663 (A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-18 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-08-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02782663?tab=results)) |
| August 17, 2026 | [Eluxadoline primary completion](https://sec-api.dev/pdufa/eluxadoline) | ABBV | Irritable Bowel Syndrome | completed | "NCT03339128 (Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-17 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03339128)) |
| Aug to Nov 2026 | [Eluxadoline topline data readout](https://sec-api.dev/pdufa/eluxadoline) | ABBV | Irritable Bowel Syndrome | scheduled | "NCT03339128 (Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-17 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03339128)) |
| August 21, 2026 | [ABBV-444 primary completion](https://sec-api.dev/pdufa/abbv-444) | ABBV | Dry Eye Disease | completed | "NCT07284381 (A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-21 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284381)) |
| Aug to Nov 2026 | [ABBV-444 topline data readout](https://sec-api.dev/pdufa/abbv-444) | ABBV | Dry Eye Disease | scheduled | "NCT07284381 (A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-08-21 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284381)) |
| Sep 2026 | [Etentamig topline data readout](https://sec-api.dev/pdufa/etentamig) | ABBV |  | completed, positive | "•In September 2026, AbbVie announced positive topline results from the Phase 3 CERVINO trial evaluating etentamig, a next-generation BCMA x CD3 bispecific T-cell engager versus investigator's choice of standard available therapies in triple-class exposed adults in R/R multiple myeloma (MM)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/abbv-20260930.htm)) |
| September 2026 | [AMJEVITA® (adalimumab) primary completion](https://sec-api.dev/pdufa/adalimumab) | ABBV | Juvenile Psoriatic Arthritis | delayed | "NCT06100744 (A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06100744)) |
| Sep to Dec 2026 | [AMJEVITA® (adalimumab) topline data readout](https://sec-api.dev/pdufa/adalimumab) | ABBV | Juvenile Psoriatic Arthritis | scheduled | "NCT06100744 (A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06100744)) |
| September 3, 2026 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Mid Face Volume Deficit | completed | "NCT07032597 (A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-03 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07032597)) |
| Sep to Dec 2026 | [AbbVie Inc. topline data readout](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Mid Face Volume Deficit | scheduled | "NCT07032597 (A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-03 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07032597)) |
| September 25, 2026 | [Juvmo (tavapadon) FDA approval](https://sec-api.dev/pdufa/tavapadon) | ABBV | To treat Parkinson’s disease in adults | completed, approved | "Juvmo \| tavapadon \| 9/25/2026 \| To treat Parkinson’s disease in adults" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| Oct 2026 | [TRUXIMA® (rituximab) topline data readout](https://sec-api.dev/pdufa/rituximab) | ABBV |  | completed, positive | "•In October 2026, AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration Epkinly in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with DLBCL." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/abbv-20260930.htm)) |
| Oct 2026 | [Lutikizumab topline data readout](https://sec-api.dev/pdufa/lutikizumab) | ABBV |  | completed, positive | "•In October 2026, AbbVie announced positive topline results from the Phase 3 INTREPID study, which evaluated lutikizumab in adults and adolescents with moderate to severe hidradenitis suppurativa (HS)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/abbv-20260930.htm)) |
| October 2026 | [Abbv-rgx-314 dose 1 primary completion](https://sec-api.dev/pdufa/abbv-rgx-314) | ABBV | AMD; nAMD; Wet Age-related Macular Degeneration | delayed | "NCT05407636 (Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05407636)) |
| Oct 2026 to Jan 2027 | [Abbv-rgx-314 dose 1 topline data readout](https://sec-api.dev/pdufa/abbv-rgx-314) | ABBV | AMD; nAMD; Wet Age-related Macular Degeneration | scheduled | "NCT05407636 (Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05407636)) |
| October 2026 | [AGN-151586 primary completion](https://sec-api.dev/pdufa/agn-151586) | ABBV | Forehead Lines | delayed | "NCT07730554 (A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07730554)) |
| Oct 2026 to Jan 2027 | [AGN-151586 topline data readout](https://sec-api.dev/pdufa/agn-151586) | ABBV | Forehead Lines | scheduled | "NCT07730554 (A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07730554)) |
| October 21, 2026 | [Venclexta (venetoclax) topline data readout](https://sec-api.dev/pdufa/venetoclax) | ABBV | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) | completed | "NCT05105841 (Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-09 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-10-21." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05105841?tab=results)) |
| October 23, 2026 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761105 SUPPL-53 (Efficacy): submission_status AP, submission_status_date 20261023, review_priority PRIORITY; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22)) |
| October 30, 2026 | [Skyrizi® (risankizumab) FDA approval](https://sec-api.dev/pdufa/risankizumab) | ABBV | moderately to severely active Crohn's disease | completed, approved | "•AbbVie announced the U.S. Food and Drug Administration (FDA) approved Skyrizi (risankizumab) for subcutaneous (SC) induction in the treatment of moderately to severely active Crohn's disease (CD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000033/abbv-20260930xexhibit991.htm)) |
| October 30, 2026 | [AbbVie Inc. earnings report](https://sec-api.dev/companies/abbv/catalysts) | ABBV |  | completed | "AbbVie Reports Third-Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000033/abbv-20260930xexhibit991.htm)) |
| October 30, 2026 | [Juvmo (tavapadon) FDA approval](https://sec-api.dev/pdufa/tavapadon) | ABBV | with Parkinson's disease | completed, approved | "•AbbVie announced the FDA approved Juvmo (tavapadon) tablets as the only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease (PD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1551152/000155115226000033/abbv-20260930xexhibit991.htm)) |
| November 2026 | [Venclexta (venetoclax) primary completion](https://sec-api.dev/pdufa/venetoclax) | ABBV | Chronic Lymphocytic Leukemia (CLL) | scheduled | "NCT04895436 (Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04895436)) |
| Nov 2026 to Feb 2027 | [Venclexta (venetoclax) topline data readout](https://sec-api.dev/pdufa/venetoclax) | ABBV | Chronic Lymphocytic Leukemia (CLL) | scheduled | "NCT04895436 (Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04895436)) |
| November 2026 | [Mirvetuximab soravtansine primary completion](https://sec-api.dev/pdufa/mirvetuximab-soravtansine) | ABBV | High Grade Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer | scheduled | "NCT05456685 (Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05456685)) |
| Nov 2026 to Feb 2027 | [Mirvetuximab soravtansine topline data readout](https://sec-api.dev/pdufa/mirvetuximab-soravtansine) | ABBV | High Grade Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer | scheduled | "NCT05456685 (Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05456685)) |
| November 2026 | [Budigalimab primary completion](https://sec-api.dev/pdufa/budigalimab) | ABBV | Hepatocellular Carcinoma | scheduled | "NCT05822752 (Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05822752)) |
| Nov 2026 to Feb 2027 | [Budigalimab topline data readout](https://sec-api.dev/pdufa/budigalimab) | ABBV | Hepatocellular Carcinoma | scheduled | "NCT05822752 (Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05822752)) |
| November 2026 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Atopic Dermatitis | scheduled | "NCT06389136 (A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06389136)) |
| Nov 2026 to Feb 2027 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Atopic Dermatitis | scheduled | "NCT06389136 (A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06389136)) |
| November 2026 | [ABBV-932 primary completion](https://sec-api.dev/pdufa/abbv-932) | ABBV | Generalized Anxiety Disorder (GAD) | scheduled | "NCT06846320 (Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06846320)) |
| Nov 2026 to Feb 2027 | [ABBV-932 topline data readout](https://sec-api.dev/pdufa/abbv-932) | ABBV | Generalized Anxiety Disorder (GAD) | scheduled | "NCT06846320 (Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06846320)) |
| November 13, 2026 | [Bimatoprost sr topline data readout](https://sec-api.dev/pdufa/bimatoprost-sr) | ABBV | Open-Angle Glaucoma; Ocular Hypertension | completed | "NCT03850782 (Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-08 (ACTUAL); Lead Sponsor AbbVie; Results First Posted 2026-11-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03850782?tab=results)) |
| December 2026 | [Abbv-rgx-314 dose 1 primary completion](https://sec-api.dev/pdufa/abbv-rgx-314) | ABBV | AMD; nAMD; Wet Age-related Macular Degeneration | scheduled | "NCT04704921 (Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04704921)) |
| Dec 2026 to Mar 2027 | [Abbv-rgx-314 dose 1 topline data readout](https://sec-api.dev/pdufa/abbv-rgx-314) | ABBV | AMD; nAMD; Wet Age-related Macular Degeneration | scheduled | "NCT04704921 (Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04704921)) |
| December 2026 | [ABBV-400 primary completion](https://sec-api.dev/pdufa/abbv-400) | ABBV | Unresectable Metastatic Colorectal Cancer | scheduled | "NCT06107413 (Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06107413)) |
| Dec 2026 to Mar 2027 | [ABBV-400 topline data readout](https://sec-api.dev/pdufa/abbv-400) | ABBV | Unresectable Metastatic Colorectal Cancer | scheduled | "NCT06107413 (Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06107413)) |
| December 2026 | [Lutikizumab primary completion](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Hidradenitis Suppurativa | scheduled | "NCT06468228 (A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06468228)) |
| Dec 2026 to Mar 2027 | [Lutikizumab topline data readout](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Hidradenitis Suppurativa | scheduled | "NCT06468228 (A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06468228)) |
| January 2027 | [Livmoniplimab primary completion](https://sec-api.dev/pdufa/livmoniplimab) | ABBV | Hepatocellular Carcinoma | scheduled | "NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06109272)) |
| Jan to Apr 2027 | [Livmoniplimab topline data readout](https://sec-api.dev/pdufa/livmoniplimab) | ABBV | Hepatocellular Carcinoma | scheduled | "NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06109272)) |
| January 2027 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Atopic Dermatitis | scheduled | "NCT06701331 (Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06701331)) |
| Jan to Apr 2027 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Atopic Dermatitis | scheduled | "NCT06701331 (Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06701331)) |
| February 2027 | [Mirvetuximab soravtansine primary completion](https://sec-api.dev/pdufa/mirvetuximab-soravtansine) | ABBV | Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive | scheduled | "NCT06365853 (A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06365853)) |
| Feb to May 2027 | [Mirvetuximab soravtansine topline data readout](https://sec-api.dev/pdufa/mirvetuximab-soravtansine) | ABBV | Recurrent Ovarian Cancer; Folate Receptor-Alpha Positive | scheduled | "NCT06365853 (A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06365853)) |
| February 2027 | [Lutikizumab primary completion](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Hidradenitis Suppurativa; Atopic Dermatitis | scheduled | "NCT06524635 (A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06524635)) |
| Feb to May 2027 | [Lutikizumab topline data readout](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Hidradenitis Suppurativa; Atopic Dermatitis | scheduled | "NCT06524635 (A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06524635)) |
| February 2027 | [MEDI0618 primary completion](https://sec-api.dev/pdufa/medi0618) | ABBV | Migraine | scheduled | "NCT06602479 (A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06602479)) |
| Feb to May 2027 | [MEDI0618 topline data readout](https://sec-api.dev/pdufa/medi0618) | ABBV | Migraine | scheduled | "NCT06602479 (A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06602479)) |
| February 2027 | [Lutikizumab primary completion](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Rheumatoid Arthritis | scheduled | "NCT06972446 (A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06972446)) |
| Feb to May 2027 | [Lutikizumab topline data readout](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Rheumatoid Arthritis | scheduled | "NCT06972446 (A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06972446)) |
| March 2027 | [Vraylar (cariprazine hydrochloride) primary completion](https://sec-api.dev/pdufa/cariprazine) | ABBV | Depression; Bipolar I Disorder | scheduled | "NCT04777357 (A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04777357)) |
| Mar to Jun 2027 | [Vraylar (cariprazine hydrochloride) topline data readout](https://sec-api.dev/pdufa/cariprazine) | ABBV | Depression; Bipolar I Disorder | scheduled | "NCT04777357 (A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04777357)) |
| March 2027 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Systemic Lupus Erythematosus | scheduled | "NCT05843643 (Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05843643)) |
| Mar to Jun 2027 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Systemic Lupus Erythematosus | scheduled | "NCT05843643 (Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05843643)) |
| March 2027 | [Risankizumab sc primary completion](https://sec-api.dev/pdufa/risankizumab-sc) | ABBV | Crohn's Disease | scheduled | "NCT06063967 (A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06063967)) |
| Mar to Jun 2027 | [Risankizumab sc topline data readout](https://sec-api.dev/pdufa/risankizumab-sc) | ABBV | Crohn's Disease | scheduled | "NCT06063967 (A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06063967)) |
| March 2027 | [Livmoniplimab primary completion](https://sec-api.dev/pdufa/livmoniplimab) | ABBV | Urothelial Carcinoma | scheduled | "NCT06632951 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06632951)) |
| Mar to Jun 2027 | [Livmoniplimab topline data readout](https://sec-api.dev/pdufa/livmoniplimab) | ABBV | Urothelial Carcinoma | scheduled | "NCT06632951 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06632951)) |
| March 2027 | [ABBV-932 primary completion](https://sec-api.dev/pdufa/abbv-932) | ABBV | Bipolar I or II Disorder | scheduled | "NCT07220460 (Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220460)) |
| Mar to Jun 2027 | [ABBV-932 topline data readout](https://sec-api.dev/pdufa/abbv-932) | ABBV | Bipolar I or II Disorder | scheduled | "NCT07220460 (Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220460)) |
| April 2027 | [Mirvetuximab soravtansine plus bevacizumab primary completion](https://sec-api.dev/pdufa/mirvetuximab-soravtansine-plus-bevacizumab) | ABBV | Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer | scheduled | "NCT05445778 (Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05445778)) |
| Apr to Jul 2027 | [Mirvetuximab soravtansine plus bevacizumab topline data readout](https://sec-api.dev/pdufa/mirvetuximab-soravtansine-plus-bevacizumab) | ABBV | Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer | scheduled | "NCT05445778 (Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05445778)) |
| May 2027 | [Ubrelvy (ubrogepant) primary completion](https://sec-api.dev/pdufa/ubrogepant) | ABBV | Migraine | scheduled | "NCT05125302 (Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05125302)) |
| May to Aug 2027 | [Ubrelvy (ubrogepant) topline data readout](https://sec-api.dev/pdufa/ubrogepant) | ABBV | Migraine | scheduled | "NCT05125302 (Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05125302)) |
| May 2027 | [Lutikizumab primary completion](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Atopic Dermatitis | scheduled | "NCT06718101 (A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06718101)) |
| May to Aug 2027 | [Lutikizumab topline data readout](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Atopic Dermatitis | scheduled | "NCT06718101 (A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06718101)) |
| June 2027 | [Venclexta (venetoclax) primary completion](https://sec-api.dev/pdufa/venetoclax) | ABBV | Multiple Myeloma | scheduled | "NCT02899052 (Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02899052)) |
| Jun to Sep 2027 | [Venclexta (venetoclax) topline data readout](https://sec-api.dev/pdufa/venetoclax) | ABBV | Multiple Myeloma | scheduled | "NCT02899052 (Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02899052)) |
| July 2027 | [Upadacitinib (abt-494) primary completion](https://sec-api.dev/pdufa/upadacitinib-abt-494) | ABBV | Ulcerative Colitis (UC) | scheduled | "NCT03006068 (A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03006068)) |
| Jul to Oct 2027 | [Upadacitinib (abt-494) topline data readout](https://sec-api.dev/pdufa/upadacitinib-abt-494) | ABBV | Ulcerative Colitis (UC) | scheduled | "NCT03006068 (A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03006068)) |
| July 2027 | [Orilissa (elagolix sodium) primary completion](https://sec-api.dev/pdufa/elagolix) | ABBV | Endometriosis | scheduled | "NCT04333576 (Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04333576)) |
| Jul to Oct 2027 | [Orilissa (elagolix sodium) topline data readout](https://sec-api.dev/pdufa/elagolix) | ABBV | Endometriosis | scheduled | "NCT04333576 (Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04333576)) |
| July 2027 | [Venclexta (venetoclax) primary completion](https://sec-api.dev/pdufa/venetoclax) | ABBV | Myelodysplastic Syndrome (MDS) | scheduled | "NCT04401748 (Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04401748)) |
| Jul to Oct 2027 | [Venclexta (venetoclax) topline data readout](https://sec-api.dev/pdufa/venetoclax) | ABBV | Myelodysplastic Syndrome (MDS) | scheduled | "NCT04401748 (Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04401748)) |
| August 2027 | [Venclexta (venetoclax) primary completion](https://sec-api.dev/pdufa/venetoclax) | ABBV | Chronic Lymphocytic Leukemia; Acute Myeloid Leukemia; Multiple Myeloma | scheduled | "NCT03844048 (An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03844048)) |
| Aug to Nov 2027 | [Venclexta (venetoclax) topline data readout](https://sec-api.dev/pdufa/venetoclax) | ABBV | Chronic Lymphocytic Leukemia; Acute Myeloid Leukemia; Multiple Myeloma | scheduled | "NCT03844048 (An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03844048)) |
| August 2027 | [Telisotuzumab adizutecan primary completion](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Metastatic Colorectal Cancer | scheduled | "NCT06614192 (A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06614192)) |
| Aug to Nov 2027 | [Telisotuzumab adizutecan topline data readout](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Metastatic Colorectal Cancer | scheduled | "NCT06614192 (A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06614192)) |
| August 2027 | [Skyrizi® (risankizumab) primary completion](https://sec-api.dev/pdufa/risankizumab) | ABBV | Ulcerative Colitis | scheduled | "NCT06880744 (A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06880744)) |
| Aug to Nov 2027 | [Skyrizi® (risankizumab) topline data readout](https://sec-api.dev/pdufa/risankizumab) | ABBV | Ulcerative Colitis | scheduled | "NCT06880744 (A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06880744)) |
| September 2027 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Crohn's Disease | scheduled | "NCT03345823 (A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03345823)) |
| Sep to Dec 2027 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Crohn's Disease | scheduled | "NCT03345823 (A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03345823)) |
| September 2027 | [AMJEVITA® (adalimumab) primary completion](https://sec-api.dev/pdufa/adalimumab) | ABBV | Ulcerative Colitis | scheduled | "NCT06257875 (A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06257875)) |
| Sep to Dec 2027 | [AMJEVITA® (adalimumab) topline data readout](https://sec-api.dev/pdufa/adalimumab) | ABBV | Ulcerative Colitis | scheduled | "NCT06257875 (A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06257875)) |
| September 2027 | [Armour thyroid primary completion](https://sec-api.dev/pdufa/armour-thyroid) | ABBV | Hypothyroidism | scheduled | "NCT06345339 (A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06345339)) |
| Sep to Dec 2027 | [Armour thyroid topline data readout](https://sec-api.dev/pdufa/armour-thyroid) | ABBV | Hypothyroidism | scheduled | "NCT06345339 (A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06345339)) |
| September 2027 | [Icalcaprant primary completion](https://sec-api.dev/pdufa/icalcaprant) | ABBV | Major Depressive Disorder | scheduled | "NCT07276997 (A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07276997)) |
| Sep to Dec 2027 | [Icalcaprant topline data readout](https://sec-api.dev/pdufa/icalcaprant) | ABBV | Major Depressive Disorder | scheduled | "NCT07276997 (A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07276997)) |
| November 2027 | [Ubrelvy (ubrogepant) primary completion](https://sec-api.dev/pdufa/ubrogepant) | ABBV | Migraine | scheduled | "NCT06417775 (Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06417775)) |
| Nov 2027 to Feb 2028 | [Ubrelvy (ubrogepant) topline data readout](https://sec-api.dev/pdufa/ubrogepant) | ABBV | Migraine | scheduled | "NCT06417775 (Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06417775)) |
| November 2027 | [Icalcaprant primary completion](https://sec-api.dev/pdufa/icalcaprant) | ABBV | Bipolar I Disorder; Bipolar II Disorder | scheduled | "NCT06696755 (A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06696755)) |
| Nov 2027 to Feb 2028 | [Icalcaprant topline data readout](https://sec-api.dev/pdufa/icalcaprant) | ABBV | Bipolar I Disorder; Bipolar II Disorder | scheduled | "NCT06696755 (A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06696755)) |
| December 2027 | [Lutikizumab primary completion](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Hidradenitis Suppurativa | scheduled | "NCT05139602 (A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05139602)) |
| Dec 2027 to Mar 2028 | [Lutikizumab topline data readout](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Hidradenitis Suppurativa | scheduled | "NCT05139602 (A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05139602)) |
| December 2027 | [Etentamig primary completion](https://sec-api.dev/pdufa/etentamig) | ABBV | Multiple Myeloma | scheduled | "NCT06158841 (Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06158841)) |
| Dec 2027 to Mar 2028 | [Etentamig topline data readout](https://sec-api.dev/pdufa/etentamig) | ABBV | Multiple Myeloma | scheduled | "NCT06158841 (Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06158841)) |
| January 2028 | [Ubrelvy (ubrogepant) primary completion](https://sec-api.dev/pdufa/ubrogepant) | ABBV | Migraine | scheduled | "NCT05127954 (Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05127954)) |
| Jan to Apr 2028 | [Ubrelvy (ubrogepant) topline data readout](https://sec-api.dev/pdufa/ubrogepant) | ABBV | Migraine | scheduled | "NCT05127954 (Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05127954)) |
| January 2028 | [IMGN151 primary completion](https://sec-api.dev/pdufa/imgn151) | ABBV | Gynecologic Cancers; Platinum-Sensitive Ovarian Cancer; Fallopian Tube Cancer | scheduled | "NCT07024784 (A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07024784)) |
| Jan to Apr 2028 | [IMGN151 topline data readout](https://sec-api.dev/pdufa/imgn151) | ABBV | Gynecologic Cancers; Platinum-Sensitive Ovarian Cancer; Fallopian Tube Cancer | scheduled | "NCT07024784 (A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07024784)) |
| February 2028 | [Skyrizi® (risankizumab) primary completion](https://sec-api.dev/pdufa/risankizumab) | ABBV | Crohn's Disease (CD) | scheduled | "NCT04524611 (Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04524611)) |
| Feb to May 2028 | [Skyrizi® (risankizumab) topline data readout](https://sec-api.dev/pdufa/risankizumab) | ABBV | Crohn's Disease (CD) | scheduled | "NCT04524611 (Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04524611)) |
| February 2028 | [Telisotuzumab vedotin primary completion](https://sec-api.dev/pdufa/telisotuzumab-vedotin) | ABBV | Non-Small Cell Lung Cancer; c-MET | scheduled | "NCT06568939 (A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568939)) |
| Feb to May 2028 | [Telisotuzumab vedotin topline data readout](https://sec-api.dev/pdufa/telisotuzumab-vedotin) | ABBV | Non-Small Cell Lung Cancer; c-MET | scheduled | "NCT06568939 (A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568939)) |
| February 2028 | [Emraclidine primary completion](https://sec-api.dev/pdufa/emraclidine) | ABBV | Schizophrenia | scheduled | "NCT07145918 (A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07145918)) |
| Feb to May 2028 | [Emraclidine topline data readout](https://sec-api.dev/pdufa/emraclidine) | ABBV | Schizophrenia | scheduled | "NCT07145918 (A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07145918)) |
| February 2028 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Skin Quality | scheduled | "NCT07880756 (Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07880756)) |
| Feb to May 2028 | [AbbVie Inc. topline data readout](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Skin Quality | scheduled | "NCT07880756 (Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07880756)) |
| March 2028 | [Qulipta (atogepant) primary completion](https://sec-api.dev/pdufa/atogepant) | ABBV | Episodic Migraine | scheduled | "NCT05711394 (A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05711394)) |
| Mar to Jun 2028 | [Qulipta (atogepant) topline data readout](https://sec-api.dev/pdufa/atogepant) | ABBV | Episodic Migraine | scheduled | "NCT05711394 (A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05711394)) |
| March 2028 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Vitiligo | scheduled | "NCT06118411 (A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06118411)) |
| Mar to Jun 2028 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Vitiligo | scheduled | "NCT06118411 (A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06118411)) |
| March 2028 | [Venclexta (venetoclax) primary completion](https://sec-api.dev/pdufa/venetoclax) | ABBV | Chronic Lymphocytic Leukemia | scheduled | "NCT06428019 (A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06428019)) |
| Mar to Jun 2028 | [Venclexta (venetoclax) topline data readout](https://sec-api.dev/pdufa/venetoclax) | ABBV | Chronic Lymphocytic Leukemia | scheduled | "NCT06428019 (A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06428019)) |
| March 2028 | [Telisotuzumab adizutecan primary completion](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Metastatic Colorectal Cancer | scheduled | "NCT06820463 (A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06820463)) |
| Mar to Jun 2028 | [Telisotuzumab adizutecan topline data readout](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Metastatic Colorectal Cancer | scheduled | "NCT06820463 (A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06820463)) |
| March 2028 | [ABBV-295 primary completion](https://sec-api.dev/pdufa/abbv-295) | ABBV | Obesity; Overweight | scheduled | "NCT07752979 (Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07752979)) |
| Mar to Jun 2028 | [ABBV-295 topline data readout](https://sec-api.dev/pdufa/abbv-295) | ABBV | Obesity; Overweight | scheduled | "NCT07752979 (Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07752979)) |
| April 2028 | [Skyrizi® (risankizumab) primary completion](https://sec-api.dev/pdufa/risankizumab) | ABBV | Psoriasis | scheduled | "NCT04862286 (Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04862286)) |
| Apr to Jul 2028 | [Skyrizi® (risankizumab) topline data readout](https://sec-api.dev/pdufa/risankizumab) | ABBV | Psoriasis | scheduled | "NCT04862286 (Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04862286)) |
| June 2028 | [Surabgene lomparvovec primary completion](https://sec-api.dev/pdufa/surabgene-lomparvovec) | ABBV | Diabetic Retinopathy | scheduled | "NCT07592273 (Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07592273)) |
| Jun to Sep 2028 | [Surabgene lomparvovec topline data readout](https://sec-api.dev/pdufa/surabgene-lomparvovec) | ABBV | Diabetic Retinopathy | scheduled | "NCT07592273 (Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07592273)) |
| June 2028 | [Botox Cosmetic (onabotulinumtoxina) primary completion](https://sec-api.dev/pdufa/onabotulinumtoxina) | ABBV | Upper Facial Lines; Glabellar Lines | scheduled | "NCT07871513 (A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07871513)) |
| Jun to Sep 2028 | [Botox Cosmetic (onabotulinumtoxina) topline data readout](https://sec-api.dev/pdufa/onabotulinumtoxina) | ABBV | Upper Facial Lines; Glabellar Lines | scheduled | "NCT07871513 (A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07871513)) |
| July 2028 | [Venclexta (venetoclax) primary completion](https://sec-api.dev/pdufa/venetoclax) | ABBV | Waldenstrom Macroglobulinemia; Lymphoplasmacytic Lymphoma | scheduled | "NCT07387471 (Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07387471)) |
| Jul to Oct 2028 | [Venclexta (venetoclax) topline data readout](https://sec-api.dev/pdufa/venetoclax) | ABBV | Waldenstrom Macroglobulinemia; Lymphoplasmacytic Lymphoma | scheduled | "NCT07387471 (Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07387471)) |
| August 2028 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Takayasu Arteritis (TAK) | scheduled | "NCT04161898 (A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04161898)) |
| Aug to Nov 2028 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Takayasu Arteritis (TAK) | scheduled | "NCT04161898 (A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04161898)) |
| August 2028 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Ulcerative Colitis | scheduled | "NCT05782907 (Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05782907)) |
| Aug to Nov 2028 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Ulcerative Colitis | scheduled | "NCT05782907 (Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05782907)) |
| August 2028 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Hidradenitis Suppurativa | scheduled | "NCT05889182 (A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05889182)) |
| Aug to Nov 2028 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Hidradenitis Suppurativa | scheduled | "NCT05889182 (A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05889182)) |
| August 2028 | [Noa lift primary completion](https://sec-api.dev/pdufa/noa-lift) | ABBV | Nasolabial Folds | scheduled | "NCT07794878 (Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794878)) |
| Aug to Nov 2028 | [Noa lift topline data readout](https://sec-api.dev/pdufa/noa-lift) | ABBV | Nasolabial Folds | scheduled | "NCT07794878 (Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVÉDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794878)) |
| September 2028 | [Skyrizi® (risankizumab) primary completion](https://sec-api.dev/pdufa/risankizumab) | ABBV | Ulcerative Colitis (UC) | scheduled | "NCT03398135 (A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03398135)) |
| Sep to Dec 2028 | [Skyrizi® (risankizumab) topline data readout](https://sec-api.dev/pdufa/risankizumab) | ABBV | Ulcerative Colitis (UC) | scheduled | "NCT03398135 (A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03398135)) |
| September 2028 | [AGN-151607-DP primary completion](https://sec-api.dev/pdufa/agn-151607-dp) | ABBV | Ventral Hernia | scheduled | "NCT07226791 (Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226791)) |
| Sep to Dec 2028 | [AGN-151607-DP topline data readout](https://sec-api.dev/pdufa/agn-151607-dp) | ABBV | Ventral Hernia | scheduled | "NCT07226791 (Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226791)) |
| September 2028 | [Telisotuzumab adizutecan primary completion](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Pancreatobiliary Cancers; Pancreatic Ductal Adenocarcinoma | scheduled | "NCT07769502 (A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07769502)) |
| Sep to Dec 2028 | [Telisotuzumab adizutecan topline data readout](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Pancreatobiliary Cancers; Pancreatic Ductal Adenocarcinoma | scheduled | "NCT07769502 (A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07769502)) |
| November 2028 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Primary Open Angle Glaucoma | scheduled | "NCT06822738 (A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06822738)) |
| Nov 2028 to Feb 2029 | [AbbVie Inc. topline data readout](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Primary Open Angle Glaucoma | scheduled | "NCT06822738 (A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06822738)) |
| November 2028 | [AGN-151607-DP primary completion](https://sec-api.dev/pdufa/agn-151607-dp) | ABBV | Upper Limb Essential Tremor | scheduled | "NCT07673107 (Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07673107)) |
| Nov 2028 to Feb 2029 | [AGN-151607-DP topline data readout](https://sec-api.dev/pdufa/agn-151607-dp) | ABBV | Upper Limb Essential Tremor | scheduled | "NCT07673107 (Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07673107)) |
| December 2028 | [RGX-314 primary completion](https://sec-api.dev/pdufa/rgx-314) | ABBV | Neovascular Age-related Macular Degeneration; Wet Macular Degeneration | scheduled | "NCT03999801 (Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03999801)) |
| Dec 2028 to Mar 2029 | [RGX-314 topline data readout](https://sec-api.dev/pdufa/rgx-314) | ABBV | Neovascular Age-related Macular Degeneration; Wet Macular Degeneration | scheduled | "NCT03999801 (Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03999801)) |
| December 2028 | [Telisotuzumab vedotin primary completion](https://sec-api.dev/pdufa/telisotuzumab-vedotin) | ABBV | Non Small Cell Lung Cancer; c-MET | scheduled | "NCT04928846 (A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04928846)) |
| Dec 2028 to Mar 2029 | [Telisotuzumab vedotin topline data readout](https://sec-api.dev/pdufa/telisotuzumab-vedotin) | ABBV | Non Small Cell Lung Cancer; c-MET | scheduled | "NCT04928846 (A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04928846)) |
| December 2028 | [ABBV-295 primary completion](https://sec-api.dev/pdufa/abbv-295) | ABBV | Moderate to Severe Psoriasis | scheduled | "NCT07933536 (A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe Psoriasis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07933536)) |
| Dec 2028 to Mar 2029 | [ABBV-295 topline data readout](https://sec-api.dev/pdufa/abbv-295) | ABBV | Moderate to Severe Psoriasis | scheduled | "NCT07933536 (A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe Psoriasis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07933536)) |
| January 2029 | [Mirvetuximab soravtansine primary completion](https://sec-api.dev/pdufa/mirvetuximab-soravtansine) | ABBV | Ovarian Cancer | scheduled | "NCT07059845 (A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07059845)) |
| Jan to Apr 2029 | [Mirvetuximab soravtansine topline data readout](https://sec-api.dev/pdufa/mirvetuximab-soravtansine) | ABBV | Ovarian Cancer | scheduled | "NCT07059845 (A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07059845)) |
| February 2029 | [Risankizumab iv primary completion](https://sec-api.dev/pdufa/risankizumab-iv) | ABBV | Crohn's Disease | scheduled | "NCT03105102 (A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03105102)) |
| Feb to May 2029 | [Risankizumab iv topline data readout](https://sec-api.dev/pdufa/risankizumab-iv) | ABBV | Crohn's Disease | scheduled | "NCT03105102 (A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03105102)) |
| February 2029 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Alopecia Areata | scheduled | "NCT07023302 (A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07023302)) |
| Feb to May 2029 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Alopecia Areata | scheduled | "NCT07023302 (A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07023302)) |
| April 2029 | [Skyrizi® (risankizumab) primary completion](https://sec-api.dev/pdufa/risankizumab) | ABBV | Crohn's Disease | scheduled | "NCT05995353 (A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05995353)) |
| Apr to Jul 2029 | [Skyrizi® (risankizumab) topline data readout](https://sec-api.dev/pdufa/risankizumab) | ABBV | Crohn's Disease | scheduled | "NCT05995353 (A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05995353)) |
| April 2029 | [ABBV-706 primary completion](https://sec-api.dev/pdufa/abbv-706) | ABBV | Small Cell Lung Cancer | scheduled | "NCT07155174 (A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07155174)) |
| Apr to Jul 2029 | [ABBV-706 topline data readout](https://sec-api.dev/pdufa/abbv-706) | ABBV | Small Cell Lung Cancer | scheduled | "NCT07155174 (A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07155174)) |
| May 2029 | [Telisotuzumab adizutecan primary completion](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Colorectal Cancer | scheduled | "NCT07525206 (A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07525206)) |
| May to Aug 2029 | [Telisotuzumab adizutecan topline data readout](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Colorectal Cancer | scheduled | "NCT07525206 (A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07525206)) |
| June 2029 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Juvenile Idiopathic Arthritis | scheduled | "NCT05609630 (Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05609630)) |
| Jun to Sep 2029 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Juvenile Idiopathic Arthritis | scheduled | "NCT05609630 (Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05609630)) |
| July 2029 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Mid Face Volume Deficit | scheduled | "NCT06734351 (A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06734351)) |
| Jul to Oct 2029 | [AbbVie Inc. topline data readout](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Mid Face Volume Deficit | scheduled | "NCT06734351 (A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06734351)) |
| July 2029 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Rheumatoid Arthritis | scheduled | "NCT07904754 (Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07904754)) |
| Jul to Oct 2029 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Rheumatoid Arthritis | scheduled | "NCT07904754 (Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07904754)) |
| August 2029 | [ABBV-701 primary completion](https://sec-api.dev/pdufa/abbv-701) | ABBV | Psoriatic Arthritis | scheduled | "NCT06865105 (Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06865105)) |
| Aug to Nov 2029 | [ABBV-701 topline data readout](https://sec-api.dev/pdufa/abbv-701) | ABBV | Psoriatic Arthritis | scheduled | "NCT06865105 (Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06865105)) |
| September 2029 | [ABBV-142 primary completion](https://sec-api.dev/pdufa/abbv-142) | ABBV | Idiopathic Pulmonary Fibrosis | scheduled | "NCT07230288 (Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07230288)) |
| Sep to Dec 2029 | [ABBV-142 topline data readout](https://sec-api.dev/pdufa/abbv-142) | ABBV | Idiopathic Pulmonary Fibrosis | scheduled | "NCT07230288 (Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07230288)) |
| October 2029 | [Telisotuzumab adizutecan primary completion](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT07744126 (A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07744126)) |
| Oct 2029 to Jan 2030 | [Telisotuzumab adizutecan topline data readout](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Head and Neck Squamous Cell Carcinoma | scheduled | "NCT07744126 (A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07744126)) |
| November 2029 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Atopic Dermatitis | scheduled | "NCT06461897 (A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06461897)) |
| Nov 2029 to Feb 2030 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Atopic Dermatitis | scheduled | "NCT06461897 (A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06461897)) |
| November 2029 | [Telisotuzumab adizutecan primary completion](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Colorectal Cancer | scheduled | "NCT07023289 (A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07023289)) |
| Nov 2029 to Feb 2030 | [Telisotuzumab adizutecan topline data readout](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Colorectal Cancer | scheduled | "NCT07023289 (A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07023289)) |
| November 2029 | [AbbVie Inc. primary completion](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Acne Scars | scheduled | "NCT07207369 (A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07207369)) |
| Nov 2029 to Feb 2030 | [AbbVie Inc. topline data readout](https://sec-api.dev/companies/abbv/catalysts) | ABBV | Acne Scars | scheduled | "NCT07207369 (A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07207369)) |
| December 2029 | [ABBV-1480 primary completion](https://sec-api.dev/pdufa/abbv-1480) | ABBV | Non-Small Cell Lung Cancer | scheduled | "NCT07756645 (A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07756645)) |
| Dec 2029 to Mar 2030 | [ABBV-1480 topline data readout](https://sec-api.dev/pdufa/abbv-1480) | ABBV | Non-Small Cell Lung Cancer | scheduled | "NCT07756645 (A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07756645)) |
| January 2030 | [ABBV-8736 primary completion](https://sec-api.dev/pdufa/abbv-8736) | ABBV | Crohn's Disease | scheduled | "NCT06548542 (Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06548542)) |
| Jan to Apr 2030 | [ABBV-8736 topline data readout](https://sec-api.dev/pdufa/abbv-8736) | ABBV | Crohn's Disease | scheduled | "NCT06548542 (Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-01 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06548542)) |
| February 2030 | [Carboplatin primary completion](https://sec-api.dev/pdufa/carboplatin) | ABBV | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | scheduled | "NCT06890338 (A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890338)) |
| Feb to May 2030 | [Carboplatin topline data readout](https://sec-api.dev/pdufa/carboplatin) | ABBV | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | scheduled | "NCT06890338 (A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-02 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890338)) |
| March 2030 | [Telisotuzumab adizutecan primary completion](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Non-Squamous Non-Small Cell Lung Cancer | scheduled | "NCT07821684 (A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07821684)) |
| Mar to Jun 2030 | [Telisotuzumab adizutecan topline data readout](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Non-Squamous Non-Small Cell Lung Cancer | scheduled | "NCT07821684 (A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-03 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07821684)) |
| April 2030 | [RINVOQ® (upadacitinib) primary completion](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Alopecia Areata | scheduled | "NCT06012240 (A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06012240)) |
| Apr to Jul 2030 | [RINVOQ® (upadacitinib) topline data readout](https://sec-api.dev/pdufa/upadacitinib) | ABBV | Alopecia Areata | scheduled | "NCT06012240 (A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06012240)) |
| September 2030 | [Telisotuzumab adizutecan primary completion](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Non-Small Cell Lung Cancer; c-MET | scheduled | "NCT07155187 (A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07155187)) |
| Sep to Dec 2030 | [Telisotuzumab adizutecan topline data readout](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV | Non-Small Cell Lung Cancer; c-MET | scheduled | "NCT07155187 (A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07155187)) |
| September 2030 | [ABBV-706 primary completion](https://sec-api.dev/pdufa/abbv-706) | ABBV | Small Cell Lung Cancer | scheduled | "NCT07365241 (A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365241)) |
| Sep to Dec 2030 | [ABBV-706 topline data readout](https://sec-api.dev/pdufa/abbv-706) | ABBV | Small Cell Lung Cancer | scheduled | "NCT07365241 (A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365241)) |
| October 2030 | [Telisotuzumab adizutecan primary completion](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV |  | scheduled | "NCT06628310 (A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06628310)) |
| Oct 2030 to Jan 2031 | [Telisotuzumab adizutecan topline data readout](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) | ABBV |  | scheduled | "NCT06628310 (A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-10 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06628310)) |

## Drugs

- [ABBV-142](https://sec-api.dev/pdufa/abbv-142): Idiopathic Pulmonary Fibrosis
- [ABBV-1480](https://sec-api.dev/pdufa/abbv-1480): Non-Small Cell Lung Cancer
- [ABBV-295](https://sec-api.dev/pdufa/abbv-295): Obesity, Moderate to Severe Psoriasis
- [ABBV-382](https://sec-api.dev/pdufa/abbv-382): Human Immuno-deficiency Virus (HIV) Disease
- [ABBV-400](https://sec-api.dev/pdufa/abbv-400): Unresectable Metastatic Colorectal Cancer
- [ABBV-444](https://sec-api.dev/pdufa/abbv-444): Dry Eye Disease
- [ABBV-701](https://sec-api.dev/pdufa/abbv-701): Psoriatic Arthritis
- [ABBV-706](https://sec-api.dev/pdufa/abbv-706): Small Cell Lung Cancer
- [ABBV-8736](https://sec-api.dev/pdufa/abbv-8736): Crohn's Disease
- [ABBV-916](https://sec-api.dev/pdufa/abbv-916): Alzheimer's Disease (AD)
- [ABBV-932](https://sec-api.dev/pdufa/abbv-932): Generalized Anxiety Disorder (GAD), Bipolar I or II Disorder, Bipolar I Disorder
- [Abbv-rgx-314 dose 1](https://sec-api.dev/pdufa/abbv-rgx-314): Diabetic Retinopathy (DR), AMD
- [AMJEVITA® (adalimumab)](https://sec-api.dev/pdufa/adalimumab): Ulcerative Colitis, Juvenile Psoriatic Arthritis
- [AGN-151586](https://sec-api.dev/pdufa/agn-151586): Forehead Lines
- [AGN-151607-DP](https://sec-api.dev/pdufa/agn-151607-dp): Upper Limb Essential Tremor, Ventral Hernia
- [Lastacaft (alcaftadine)](https://sec-api.dev/pdufa/alcaftadine): 
- [Armour thyroid](https://sec-api.dev/pdufa/armour-thyroid): Hypothyroidism
- [Qulipta (atogepant)](https://sec-api.dev/pdufa/atogepant): Migraine, Menstrual Migraine (MM), Chronic Migraine, Episodic Migraine
- [Avibactam](https://sec-api.dev/pdufa/avibactam): complicated intra-abdominal infections
- [Emblaveo (avibactam sodium; aztreonam)](https://sec-api.dev/pdufa/avibactam-aztreonam): 
- [Avycaz (avibactam sodium; ceftazidime)](https://sec-api.dev/pdufa/avibactam-ceftazidime): 
- [Durysta (bimatoprost)](https://sec-api.dev/pdufa/bimatoprost): 
- [Bimatoprost sr](https://sec-api.dev/pdufa/bimatoprost-sr): Open-Angle Glaucoma
- [Botox](https://sec-api.dev/pdufa/botox): Masseter Muscle Prominence
- [Budigalimab](https://sec-api.dev/pdufa/budigalimab): Hepatocellular Carcinoma
- [Vraylar (cariprazine hydrochloride)](https://sec-api.dev/pdufa/cariprazine): Depression
- [Cariprazine flexible dose](https://sec-api.dev/pdufa/cariprazine-flexible-dose): Schizophrenia
- [Dalvance (dalbavancin hydrochloride)](https://sec-api.dev/pdufa/dalbavancin): 
- [Viekira Xr (dasabuvir sodium; ombitasvir; paritaprevir; ritonavir)](https://sec-api.dev/pdufa/dasabuvir-ombitasvir-paritaprevir-ritonavir): 
- [Orilissa (elagolix sodium)](https://sec-api.dev/pdufa/elagolix): Endometriosis
- [Oriahnn (Copackaged) (elagolix sodium; elagolix sodium,estradiol,norethindrone acetate)](https://sec-api.dev/pdufa/elagolix-elagolix-estradiol-norethindrone): 
- [Elezanumab](https://sec-api.dev/pdufa/elezanumab): Spinal Cord Injury (SCI)
- [Eluxadoline](https://sec-api.dev/pdufa/eluxadoline): Irritable Bowel Syndrome
- [Emraclidine](https://sec-api.dev/pdufa/emraclidine): Schizophrenia
- [Lexapro (escitalopram oxalate)](https://sec-api.dev/pdufa/escitalopram-oxalate): 
- [Etentamig](https://sec-api.dev/pdufa/etentamig): Multiple Myeloma
- [Foscarbidopa](https://sec-api.dev/pdufa/foscarbidopa): Parkinson's Disease (PD)
- [Vyalev (foscarbidopa; foslevodopa)](https://sec-api.dev/pdufa/foscarbidopa-foslevodopa): 
- [Glecaprevir](https://sec-api.dev/pdufa/glecaprevir): 
- [Mavyret (glecaprevir; pibrentasvir)](https://sec-api.dev/pdufa/glecaprevir-pibrentasvir): 
- [GM-2505](https://sec-api.dev/pdufa/gm-2505): Major Depressive Disorder
- [GUB014295](https://sec-api.dev/pdufa/gub014295): moderate to severe glabellar lines
- [Imbruvica (ibrutinib)](https://sec-api.dev/pdufa/ibrutinib): Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia
- [Icalcaprant](https://sec-api.dev/pdufa/icalcaprant): Major Depressive Disorder, Bipolar I Disorder
- [IMGN151](https://sec-api.dev/pdufa/imgn151): Gynecologic Cancers
- [Irritable bowel syndrome with constipation (ibs-c) participants (lin-md-63 and lin-md-64 completers)](https://sec-api.dev/pdufa/irritable-bowel-syndrome-with-constipation-ibs-c-participants-lin-md-63-and-lin-): Irritable Bowel Syndrome With Constipation
- [Lupron Depot (leuprolide acetate)](https://sec-api.dev/pdufa/leuprolide): 
- [Fetzima (levomilnacipran hydrochloride)](https://sec-api.dev/pdufa/levomilnacipran): 
- [LINZESS® (linaclotide)](https://sec-api.dev/pdufa/linaclotide): functional constipation, Functional Constipation (FC)
- [Livmoniplimab](https://sec-api.dev/pdufa/livmoniplimab): Hepatocellular Carcinoma, Urothelial Carcinoma
- [Lutikizumab](https://sec-api.dev/pdufa/lutikizumab): Rheumatoid Arthritis, Hidradenitis Suppurativa, Atopic Dermatitis
- [MEDI0618](https://sec-api.dev/pdufa/medi0618): Migraine
- [Mirvetuximab soravtansine](https://sec-api.dev/pdufa/mirvetuximab-soravtansine): Advanced High-Grade Epithelial Ovarian Cancer, Recurrent Ovarian Cancer, High Grade Ovarian Cancer, Ovarian Cancer
- [Mirvetuximab soravtansine plus bevacizumab](https://sec-api.dev/pdufa/mirvetuximab-soravtansine-plus-bevacizumab): Ovarian Cancer
- [Byvalson (nebivolol hydrochloride; valsartan)](https://sec-api.dev/pdufa/nebivolol-valsartan): 
- [Noa lift](https://sec-api.dev/pdufa/noa-lift): Nasolabial Folds
- [Nx-13 250mg](https://sec-api.dev/pdufa/nx-13): Ulcerative Colitis
- [GAZYVA® (obinutuzumab)](https://sec-api.dev/pdufa/obinutuzumab): 
- [Botox Cosmetic (onabotulinumtoxina)](https://sec-api.dev/pdufa/onabotulinumtoxina): Forehead Lines, Upper Facial Lines
- [Paricalcitol](https://sec-api.dev/pdufa/paricalcitol): Chronic Kidney Disease (CKD)
- [Vuity (pilocarpine hydrochloride)](https://sec-api.dev/pdufa/pilocarpine): 
- [Pivekimab](https://sec-api.dev/pdufa/pivekimab): 
- [Decnupaz (pivekimab sunirine-pvzy)](https://sec-api.dev/pdufa/pivekimab-sunirine-pvzy): To treat adults with blastic plasmacytoid dendritic cell neoplasm
- [Lucentis® (ranibizumab)](https://sec-api.dev/pdufa/ranibizumab): neovascular, Neovascular Age-Related Macular Degeneration (nAMD)
- [RGX-314](https://sec-api.dev/pdufa/rgx-314): Neovascular Age-related Macular Degeneration
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab): moderately to severely active crohn's disease, Crohn's Disease (CD), Crohn's Disease, Ulcerative Colitis (UC), Ulcerative Colitis, Psoriasis
- [Risankizumab iv](https://sec-api.dev/pdufa/risankizumab-iv): Crohn's Disease
- [Skyrizi (risankizumab-rzaa)](https://sec-api.dev/pdufa/risankizumab-rzaa): 
- [Risankizumab sc](https://sec-api.dev/pdufa/risankizumab-sc): Crohn's Disease
- [Norvir (ritonavir)](https://sec-api.dev/pdufa/ritonavir): 
- [Surabgene lomparvovec](https://sec-api.dev/pdufa/surabgene-lomparvovec): Diabetic Retinopathy
- [Juvmo (tavapadon)](https://sec-api.dev/pdufa/tavapadon): with parkinson's disease, parkinson's disease, To treat Parkinson’s disease in adults, Parkinson Disease
- [Telisotuzumab adizutecan](https://sec-api.dev/pdufa/telisotuzumab-adizutecan): Colorectal Cancer, Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Pancreatobiliary Cancers, Non-Squamous Non-Small Cell Lung Cancer
- [Telisotuzumab vedotin](https://sec-api.dev/pdufa/telisotuzumab-vedotin): Non Small Cell Lung Cancer, Non-small Cell Lung Cancer
- [Emrelis (telisotuzumab vedotin-tllv)](https://sec-api.dev/pdufa/telisotuzumab-vedotin-tllv): 
- [Ubrelvy (ubrogepant)](https://sec-api.dev/pdufa/ubrogepant): Migraine
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib): with moderately to severely active ulcerative colitis, with giant cell arteritis, Crohn's Disease, Alopecia Areata, Atopic Dermatitis, Systemic Lupus Erythematosus, Juvenile Idiopathic Arthritis, Takayasu Arteritis (TAK)
- [Upadacitinib (abt-494)](https://sec-api.dev/pdufa/upadacitinib-abt-494): Ulcerative Colitis (UC)
- [Venclexta (venetoclax)](https://sec-api.dev/pdufa/venetoclax): Chronic Lymphocytic Leukemia (CLL), Myelodysplastic Syndrome (MDS), Multiple Myeloma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Acute Myeloid Leukemia (AML)
- [Viibryd (vilazodone hydrochloride)](https://sec-api.dev/pdufa/vilazodone): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/abbv/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ABBV catalysts: AbbVie Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/abbv/catalysts

```bibtex
@misc{secapidev_companies_abbv_catalysts_20261116,
  title        = {ABBV catalysts: AbbVie Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/abbv/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_abbv_catalysts_20261116","title":"ABBV catalysts: AbbVie Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/abbv/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
